Skip to main content
OpenTrials
Completed

NCT Number: NCT04283318

Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes

In a previous study investigating the effects of intermittent fasting, our research group found evidence for higher glucose excursions and a reduced insulin response after a 36 hour fasting period as compared to an overnight fasting period in healthy subjects.

The aim of this research project is to investigate the effect of short and midterm fasting (12 hours versus 36 hours) on glucose metabolism, glucose regulatory hormones, insulin secretion and resting energy expenditure in healthy and obese people as well as in patients with type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

About this study

In this clinical study, we want to examine the effects of different fasting periods (12 hours versus 36 hours) on blood sugar levels and other metabolic parameters and hormones. For this the following investigations are carried out:

  • Oral glucose tolerance test with detailed laboratory evaluation
  • Bio-impedance measurement to determine body composition (muscle and fat mass)

The examinations are carried out on 4 different cohorts (normal healthy persons, obese patients, patients with type 2 diabetes and patients with type 1 diabetes).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Gender: Both, male and female Minimum Age: 18 years

Inclusion criteria

Cohort I (Healthy, non-obese subjects) Age >18 years; body mass index in the range of 20.0-27.0 kg/m2; fasting plasma glucose <110mg/dL

Inclusion criteria

cohort II (Obese subjects) Age >18 years; body mass index >30 kg/m2; fasting plasma glucose <110mg/dL

Inclusion criteria

Cohort III (Cohort with subjects with Type 2 Diabetes Mellitus) Age >18 years; established Diabetes mellitus type 2 on either diet or a monotherapy or combination of metformin, Dipeptidylpeptidase (DPP)-4-inhibitors or sulfonylurea

Inclusion criteria

Cohort IV (Cohort with subjects with Type 1 Diabetes Mellitus) Age >18 years; diagnosed with Type 1 Diabetes Mellitus >12 months; treated with multiple daily Insulin injectioins (MDII) or continuous subcutaneous Insulin Infusion (CSII); stable Insulin therapy as clinically assessed by the study physician; C-Peptide negative defined as 0.3 nmol/L; HbA1c <9.5%; no diabetic ketoacidosis within the last 12 months; no severe hypoglycaemia requiring external assistance within the last 12 months; running on the FreeStyle Libre 1 (Abbott, USA) intermittently-viewed continuous Glucose Monitoring System (iCGM) as Standard of care for Glucose monitoring

Exclusion criteria

(for all participants) History of cardiovascular disease; acute or chronic inflammatory disorder; heavy drinking (more than 15 drinks/week); dietary restrictions (e.g. vegetarianism and vegan); insulin Treatment (excluded subjects with Type 1 Diabetes Mellitus); corticosteroid therapy; known malignancy; women who are pregnant, breast-feeding or trying to become pregnant; history of any chronic disease process that could interfere with interpretation of study results; therapy with antidepressants within past 6 months

Treatment and study plan

12h fasting

Behavioral

12h fasting (overnight)

36h fasting

Behavioral

36h fasting ( one day and two nights fasting)

Primary outcomes

  1. change of 2h glucose levels

    Time frame: after 12 and 36 hours of fasting

    Difference in the change of 2h glucose levels in an oral glucose tolerance test

Secondary outcomes

  1. changes in insulin sensitivity (QUICKI)

    Time frame: after 12 and 36 hours of fasting

    differences in QUICKI

  2. changes in insulin sensitivity (Matsuda Index)

    Time frame: after 12 and 36 hours of fasting

    differences in Matsuda Index

  3. changes in insulin sensitivity (ISI)

    Time frame: after 12 and 36 hours of fasting

    differences in ISI

  4. changes in insulin sensitivity (HOMA-Index)

    Time frame: after 12 and 36 hours of fasting

    differences in HOMA-Index

  5. Changes in glycaemic pattern

    Time frame: after 12 and 36 hours of fasting

    differences in area under the curve (AUC) of glycaemic pattern in Oral glucose tolerance test

  6. Changes in body composition

    Time frame: after 12 and 36 hours of fasting

    differences in bioimpedance analysis

Sponsors and collaborators

Lead sponsor

Medical University of Graz

Other

Registry information

Official study title

The Effects of Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes

Acronym: PROLOG

Important dates

Study start
2018
Primary completion
2020
Study completion
2022
First posted
Feb 25, 2020
Registry last updated
Mar 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.